{"id":83339,"date":"2025-12-09T10:30:22","date_gmt":"2025-12-09T10:30:22","guid":{"rendered":"https:\/\/www.cofb.org\/?p=83339"},"modified":"2025-12-17T11:48:00","modified_gmt":"2025-12-17T11:48:00","slug":"farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","title":{"rendered":"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica"},"content":{"rendered":"\n

Al llarg del mes de novembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> va organitzar una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC)<\/a><\/strong> i amb el patrocini d\u2019AstraZeneca<\/strong><\/a>, Bristol Myers Squibb <\/a><\/strong>i Janssen<\/strong><\/a>. El vocal d\u2019Hospitals del COFB, David Conde<\/strong>, va coordinar i moderar el curs adre\u00e7at a farmac\u00e8utics i farmac\u00e8utiques d\u2019hospitals.<\/p>\n\n\n\n

Els objectius<\/strong> de la formaci\u00f3 van ser actualitzar la gesti\u00f3 i el tractament dels diferents c\u00e0ncers hematol\u00f2gics<\/strong> i revisar els aspectes relacionats amb l’atenci\u00f3 farmac\u00e8utica<\/strong> en la dispensaci\u00f3 de tractaments<\/strong> per combatre aquest tipus de c\u00e0ncers.<\/p>\n\n\n\n

\"El<\/a>
El vocal d’Hospitals del COFB, David Conde, durant la presentaci\u00f3 del curs “Actualitzaci\u00f3 en oncologia hematol\u00f2gica”.<\/figcaption><\/figure>\n\n\n\n

David Conde va afirmar que, davant la bona acollida pels assistents, \u201cels cursos d\u2019actualitzaci\u00f3 en malalties hematol\u00f2giques comencen a ser una tradici\u00f3 anual. Aquest any s\u2019ha posat el focus en el mieloma m\u00faltiple<\/strong> amb dues sessions: el limfoma fol\u00b7licular<\/strong> i el limfoma de c\u00e8l\u00b7lules del mantell<\/strong>\u201d.<\/p>\n\n\n\n

El vocal d\u2019Hospitals del COFB va remarcar que el curs \u201cha perm\u00e8s oferir una visi\u00f3 essencial de la r\u00e0pida evoluci\u00f3 de l’oncologia hematol\u00f2gica<\/strong>, amb noves actualitzacions en el futur. El curs confirma que l’objectiu de la curaci\u00f3 o control de la malaltia<\/strong>, abans inassolible en diverses hemopaties, \u00e9s ara un horitz\u00f3 terap\u00e8utic real\u201d.<\/p>\n\n\n\n

Combinacions de f\u00e0rmacs enfront el mieloma m\u00faltiple de nou diagn\u00f2stic<\/h2>\n\n\n\n

En la primera sessi\u00f3 del curs, que va tenir lloc el 6 de novembre, el cap del Servei d’Hematologia de l\u2019Hospital Cl\u00ednic, Carlos Fern\u00e1ndez<\/strong>, es va focalitzar en el tractament del mieloma m\u00faltiple en pacients triples<\/strong>: \u201cel pron\u00f2stic empitjora amb cada l\u00ednia de ter\u00e0pia successiva, amb una superviv\u00e8ncia lliure de progressi\u00f3<\/strong> (mPFS) per als triple-refractaris d’entre 3,4 i 4,6 mesos. Davant d’aquest escenari, s’ha expandit l’arsenal terap\u00e8utic amb immunoter\u00e0pies innovadores\u201d.<\/p>\n\n\n\n

\"L'hemat\u00f2leg<\/a>
L’hemat\u00f2leg Carlos Fern\u00e1ndez durant la seva exposici\u00f3 sobre el mieloma m\u00faltiple en pacients triples.<\/figcaption><\/figure>\n\n\n\n

A continuaci\u00f3, Larrea va analitzar el potencial de les ter\u00e0pies de c\u00e8l\u00b7lules T amb receptor d’antigen quim\u00e8ric<\/strong> (CAR-T) dirigides a BCMA (ide-cel, cilta-cel) i els anticossos biespec\u00edfics<\/strong> (BsAb) dirigits a BCMA (teclistamab, elranatamab) o GPRC5D (talquetamab). Va assenyalar que aquestes noves ter\u00e0pies han demostrat altes taxes de resposta<\/strong>, per\u00f2 comporten la necessitat de gestionar toxicitats espec\u00edfiques com la s\u00edndrome d’alliberament de citocines (CRS), la neurotoxicitat (ICANS) i el risc d’infeccions per citop\u00e8nies persistents.<\/p>\n\n\n\n

Tractament del mieloma m\u00faltiple recividant\/refractari<\/h2>\n\n\n\n

El 13 de novembre, en la segona sessi\u00f3 del curs, Albert Oriol<\/strong>, hemat\u00f2leg de l\u2019Institut Catal\u00e0 d\u2019Oncologia Josep Carreras Research Institute<\/strong>, va centrar la seva pon\u00e8ncia amb el mieloma m\u00faltiple de nou diagn\u00f2stic<\/strong>: \u201cel tractament inicial ha pivotat cap a les combinacions de quatre f\u00e0rmacs<\/strong> (quadruplets), que inclouen un antic\u00f2s monoclonal anti-CD38, un inhibidor del proteasoma (IP), un agent immunomodulador (IMID) i un corticoide. L’objectiu fonamental d’aquesta intensificaci\u00f3 \u00e9s aconseguir una resposta profunda i r\u00e0pida<\/strong>, especialment la negativitat de la malaltia residual m\u00ednima (MRD)\u201d.<\/p>\n\n\n\n

\"\"<\/a>
El doctor Albert Oriol durant la seva presentaci\u00f3 lligada a mieloma m\u00faltiple de nou diagn\u00f2stic.<\/figcaption><\/figure>\n\n\n\n

Pel que fa a l\u2019elecci\u00f3 de la combinaci\u00f3 ideal de f\u00e0rmacs<\/strong>, l\u2019hemat\u00f2leg va compartir que tot dep\u00e8n de la idone\u00eftat per al trasplantament aut\u00f2leg de c\u00e8l\u00b7lules mare <\/strong>(ASCT), els qu\u00e0druplets han mostrat benefici en la profunditat de la resposta en tots els perfils de pacients. Un aspecte cr\u00edtic esmentat \u00e9s que la combinaci\u00f3 d’IMIDs<\/strong> i anticossos anti-CD38<\/strong> augmenta significativament el risc d’infeccions, principalment pneum\u00f2nia, sobretot durant els primers 3-6 mesos.<\/p>\n\n\n\n

Actualitzaci\u00f3 sobre el limfoma de c\u00e8l\u00b7lules del mantell<\/h2>\n\n\n\n

La Dra. Ana Mar\u00edn<\/strong>, hemat\u00f2loga del Vall d\u2019Hebron Institut d\u2019Oncologia, va compartir el 20 de novembre una actualitzaci\u00f3 sobre el limfoma de c\u00e8l\u00b7lules del mantell<\/strong> (LCM). Va indicar que, hist\u00f2ricament, el LCM ha estat considerat incurable, per\u00f2 es viu un canvi de paradigma amb la introducci\u00f3 dels inhibidors de la tirosina cinasa de Bruton (iBTK) en el tractament de primera l\u00ednia (1L). En pacients joves aptes, l’assaig TRIANGLE va demostrar que afegir ibrutinib a l’est\u00e0ndard de tractament (SOC) millora la superviv\u00e8ncia, cosa que posa en q\u00fcesti\u00f3 la necessitat del trasplantament aut\u00f2leg de c\u00e8l\u00b7lules mare (ASCT) en l\u2019actualitat.<\/p>\n\n\n\n

\"L'hemat\u00f2loga<\/a>
L’hemat\u00f2loga Ana Mar\u00edn en un moment del curs “Actualitzaci\u00f3 en oncologia hematol\u00f2gica”<\/figcaption><\/figure>\n\n\n\n

En pacients grans o no aptes per a trasplantament<\/strong>, Mar\u00edn va fer refer\u00e8ncia a l’assaig ECHO (acalabrutinib + R-Bendamustina), on es va mostrar una millora en la PFS. Va explicar que “en l’escenari de recaiguda\/refractarietat (R\/R), els iBTK covalents s\u00f3n el nou est\u00e0ndard de tractament. Per als pacients que recauen despr\u00e9s de l’iBTK, les opcions de rescat inclouen la ter\u00e0pia CAR-T (brexucel) i el pirtobrutinib (un iBTK no covalent). Totes aquestes ter\u00e0pies poden anar avan\u00e7ant a tractaments m\u00e9s preco\u00e7os”.<\/p>\n\n\n\n

\u00daltimes novetats lligades al limfoma fol\u00b7licular<\/h2>\n\n\n\n

Finalment, en la darrera sessi\u00f3 que es va celebrar el 27 de novembre, el doctor Juan Manuel Sancho<\/strong> (ICO-Hospital Germans Trias i Pujol) va fer la presentaci\u00f3 sobre el limfoma fol\u00b7licular (LF): \u201cla presa de decisions en el LF es basa en l’estadi i la c\u00e0rrega tumoral, utilitzant criteris com els de GELF. Per al LF avan\u00e7at amb alta c\u00e0rrega tumoral, l’est\u00e0ndard continua sent la immunoquimioter\u00e0pia (com R-CHOP o R-bendamustina) seguida de manteniment amb rituximab.<\/p>\n\n\n\n

\"El<\/a>
El doctor Juan Manuel Sancho durant la seva intervenci\u00f3 lligada al limfoma fol\u00b7licular.<\/figcaption><\/figure>\n\n\n\n

L’\u00fas de rituximab<\/strong> com a manteniment<\/strong>, \u201ctot i que millora significativament la superviv\u00e8ncia lliure de progressi\u00f3 (PFS), no ha mostrat un impacte clar en la superviv\u00e8ncia global (OS) a llarg termini\u201d, va afirmar Sancho. En el context de la recaiguda\/refractarietat (R\/R)<\/strong>, especialment per a pacients amb progressi\u00f3 preco\u00e7 (POD24), el doctor va recalcar que \u201cl’opci\u00f3 de lenalidomida m\u00e9s rituximab (R2) ha millorat la PFS. Per a les recaigudes posteriors, les opcions de tractament inclouen els anticossos biespec\u00edfics (mosunetuzumab, epcoritamab) i les ter\u00e0pies CAR T-cells (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel), que ofereixen altes taxes de resposta\u201d.<\/p>\n\n\n\n

Amb la col\u00b7laboraci\u00f3 de:<\/strong><\/p>\n\n\n\n

\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure><\/div>\n<\/div>\n<\/div>\n\n\n\n

Amb el patrocini de:<\/strong><\/p>\n\n\n\n

\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Al llarg del mes de novembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va organitzar una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i amb el patrocini d\u2019AstraZeneca, Bristol Myers Squibb i Janssen. El vocal d\u2019Hospitals del COFB, […]<\/p>\n","protected":false},"author":10,"featured_media":83398,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[3127,18,19,50,122,70,5425,1044,1046,63],"class_list":["post-83339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-actualitzacio","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-diagnostic","tag-farmaceutics-hospitalaris","tag-formacio","tag-linfoma","tag-mieloma","tag-oncologia-hematologica","tag-tractament"],"yoast_head":"\nFarmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-09T10:30:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-17T11:48:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1383\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Xavier Magraner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Xavier Magraner\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\"},\"author\":{\"name\":\"Xavier Magraner\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\"},\"headline\":\"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica\",\"datePublished\":\"2025-12-09T10:30:22+00:00\",\"dateModified\":\"2025-12-17T11:48:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\"},\"wordCount\":1116,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"keywords\":[\"actualitzaci\u00f3\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"diagn\u00f2stic\",\"farmac\u00e8utics hospitalaris\",\"Formaci\u00f3\",\"linfoma\",\"mieloma\",\"oncologia hematol\u00f2gica\",\"tractament\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\",\"url\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\",\"name\":\"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"datePublished\":\"2025-12-09T10:30:22+00:00\",\"dateModified\":\"2025-12-17T11:48:00+00:00\",\"description\":\"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg\",\"width\":2560,\"height\":1383,\"caption\":\"Blood cells\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\",\"name\":\"Xavier Magraner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"caption\":\"Xavier Magraner\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","og_locale":"ca_ES","og_type":"article","og_title":"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d","og_url":"https:\/\/www.cofb.org\/ca\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2025-12-09T10:30:22+00:00","article_modified_time":"2025-12-17T11:48:00+00:00","og_image":[{"width":2560,"height":1383,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","type":"image\/jpeg"}],"author":"Xavier Magraner","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Xavier Magraner"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/"},"author":{"name":"Xavier Magraner","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4"},"headline":"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica","datePublished":"2025-12-09T10:30:22+00:00","dateModified":"2025-12-17T11:48:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/"},"wordCount":1116,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","keywords":["actualitzaci\u00f3","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","diagn\u00f2stic","farmac\u00e8utics hospitalaris","Formaci\u00f3","linfoma","mieloma","oncologia hematol\u00f2gica","tractament"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","url":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/","name":"Farmac\u00e8utics hospitalaris s'actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","datePublished":"2025-12-09T10:30:22+00:00","dateModified":"2025-12-17T11:48:00+00:00","description":"El passat novembre, el COFB va organitzar, conjuntament amb la SCFC, una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg","width":2560,"height":1383,"caption":"Blood cells"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2025\/12\/09\/farmaceutics-hospitalaris-sactualitzen-al-cofb-en-una-nova-edicio-de-la-formacio-en-oncologia-hematologica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Farmac\u00e8utics hospitalaris s’actualitzen al COFB en una nova edici\u00f3 de la formaci\u00f3 en oncologia hematol\u00f2gica"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4","name":"Xavier Magraner","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","caption":"Xavier Magraner"},"url":"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-scaled.jpg",2560,1383,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-300x162.jpg",300,162,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-768x415.jpg",768,415,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-1024x553.jpg",1024,553,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-1536x830.jpg",1536,830,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-2048x1106.jpg",2048,1106,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/12\/oncologia-hematologica_original-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Xavier Magraner","author_link":"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/"},"uagb_comment_info":0,"uagb_excerpt":"Al llarg del mes de novembre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va organitzar una nova edici\u00f3 del curs \u201cActualitzaci\u00f3 en oncologia hematol\u00f2gica\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i amb el patrocini d\u2019AstraZeneca, Bristol Myers Squibb i Janssen. El vocal d\u2019Hospitals del COFB, […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/83339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=83339"}],"version-history":[{"count":42,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/83339\/revisions"}],"predecessor-version":[{"id":83426,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/83339\/revisions\/83426"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/83398"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=83339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=83339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=83339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}